Oral Ondansetron Pharmacokinetics

The Effect of Chemotherapy

Poe‐Hirr ‐H Hsyu, J. Frederick Pritchard, Haig P. Bozigian, Ann E. Gooding, Rita H. Griffin, Rodney Mitchell, Toni Bjurstrom, Timothy Panella, Andrew T. Huang, Lea Ann Hansen

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The effect of a typical 5‐day chemotherapy treatment with cisplatin (20–40 mg/m 2 per day) and 5‐fluorouracil (5‐FU, 1 gm/m 2 per day) on the pharmacokinetics of ondansetron was investigated. Twenty cancer patients received 8 mg of ondansetron in three periods, including an oral tablet on day 1, an intravenous infusion on day 4, and an oral tablet on day 5. Absolute bioavailability after the oral dosing on day 1 was 87.5 ± 31.3%, and on day 5 was 85.2 ± 22.1% (P > .05). Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 ± 275 and 381 ± 222 ng · hour/mL, 53.3 ± 26.8 and 43.6 ± 21.7 ng/mL, 1.9 ± 1.4 and 2± 1.4 hours, and 5.21 ± 1.78 and 6.19 ± 1.99 hours, respectively. These values were not significantly different (P > .05). In summary, this study showed that cisplatin and 5‐FU did not significantly alter the pharmacokinetics of oral ondansetron in cancer patients during the 5 days of chemotherapy. Oral bioavailability of ondansetron appeared to be greater in cancer patients than in healthy subjects. 1994 American College of Clinical Pharmacology

Original languageEnglish (US)
Pages (from-to)767-773
Number of pages7
JournalThe Journal of Clinical Pharmacology
Volume34
Issue number7
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Ondansetron
Pharmacokinetics
Drug Therapy
Fluorouracil
Cisplatin
Biological Availability
Tablets
Neoplasms
Clinical Pharmacology
Intravenous Infusions
Area Under Curve
Half-Life
Healthy Volunteers
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hsyu, PH. H., Pritchard, J. F., Bozigian, H. P., Gooding, A. E., Griffin, R. H., Mitchell, R., ... Hansen, L. A. (1994). Oral Ondansetron Pharmacokinetics: The Effect of Chemotherapy. The Journal of Clinical Pharmacology, 34(7), 767-773. https://doi.org/10.1002/j.1552-4604.1994.tb02038.x

Oral Ondansetron Pharmacokinetics : The Effect of Chemotherapy. / Hsyu, Poe‐Hirr ‐H; Pritchard, J. Frederick; Bozigian, Haig P.; Gooding, Ann E.; Griffin, Rita H.; Mitchell, Rodney; Bjurstrom, Toni; Panella, Timothy; Huang, Andrew T.; Hansen, Lea Ann.

In: The Journal of Clinical Pharmacology, Vol. 34, No. 7, 01.01.1994, p. 767-773.

Research output: Contribution to journalArticle

Hsyu, PHH, Pritchard, JF, Bozigian, HP, Gooding, AE, Griffin, RH, Mitchell, R, Bjurstrom, T, Panella, T, Huang, AT & Hansen, LA 1994, 'Oral Ondansetron Pharmacokinetics: The Effect of Chemotherapy', The Journal of Clinical Pharmacology, vol. 34, no. 7, pp. 767-773. https://doi.org/10.1002/j.1552-4604.1994.tb02038.x
Hsyu PHH, Pritchard JF, Bozigian HP, Gooding AE, Griffin RH, Mitchell R et al. Oral Ondansetron Pharmacokinetics: The Effect of Chemotherapy. The Journal of Clinical Pharmacology. 1994 Jan 1;34(7):767-773. https://doi.org/10.1002/j.1552-4604.1994.tb02038.x
Hsyu, Poe‐Hirr ‐H ; Pritchard, J. Frederick ; Bozigian, Haig P. ; Gooding, Ann E. ; Griffin, Rita H. ; Mitchell, Rodney ; Bjurstrom, Toni ; Panella, Timothy ; Huang, Andrew T. ; Hansen, Lea Ann. / Oral Ondansetron Pharmacokinetics : The Effect of Chemotherapy. In: The Journal of Clinical Pharmacology. 1994 ; Vol. 34, No. 7. pp. 767-773.
@article{cc9295466e9a46b2a4d6d252640730d3,
title = "Oral Ondansetron Pharmacokinetics: The Effect of Chemotherapy",
abstract = "The effect of a typical 5‐day chemotherapy treatment with cisplatin (20–40 mg/m 2 per day) and 5‐fluorouracil (5‐FU, 1 gm/m 2 per day) on the pharmacokinetics of ondansetron was investigated. Twenty cancer patients received 8 mg of ondansetron in three periods, including an oral tablet on day 1, an intravenous infusion on day 4, and an oral tablet on day 5. Absolute bioavailability after the oral dosing on day 1 was 87.5 ± 31.3{\%}, and on day 5 was 85.2 ± 22.1{\%} (P > .05). Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 ± 275 and 381 ± 222 ng · hour/mL, 53.3 ± 26.8 and 43.6 ± 21.7 ng/mL, 1.9 ± 1.4 and 2± 1.4 hours, and 5.21 ± 1.78 and 6.19 ± 1.99 hours, respectively. These values were not significantly different (P > .05). In summary, this study showed that cisplatin and 5‐FU did not significantly alter the pharmacokinetics of oral ondansetron in cancer patients during the 5 days of chemotherapy. Oral bioavailability of ondansetron appeared to be greater in cancer patients than in healthy subjects. 1994 American College of Clinical Pharmacology",
author = "Hsyu, {Poe‐Hirr ‐H} and Pritchard, {J. Frederick} and Bozigian, {Haig P.} and Gooding, {Ann E.} and Griffin, {Rita H.} and Rodney Mitchell and Toni Bjurstrom and Timothy Panella and Huang, {Andrew T.} and Hansen, {Lea Ann}",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/j.1552-4604.1994.tb02038.x",
language = "English (US)",
volume = "34",
pages = "767--773",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Oral Ondansetron Pharmacokinetics

T2 - The Effect of Chemotherapy

AU - Hsyu, Poe‐Hirr ‐H

AU - Pritchard, J. Frederick

AU - Bozigian, Haig P.

AU - Gooding, Ann E.

AU - Griffin, Rita H.

AU - Mitchell, Rodney

AU - Bjurstrom, Toni

AU - Panella, Timothy

AU - Huang, Andrew T.

AU - Hansen, Lea Ann

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The effect of a typical 5‐day chemotherapy treatment with cisplatin (20–40 mg/m 2 per day) and 5‐fluorouracil (5‐FU, 1 gm/m 2 per day) on the pharmacokinetics of ondansetron was investigated. Twenty cancer patients received 8 mg of ondansetron in three periods, including an oral tablet on day 1, an intravenous infusion on day 4, and an oral tablet on day 5. Absolute bioavailability after the oral dosing on day 1 was 87.5 ± 31.3%, and on day 5 was 85.2 ± 22.1% (P > .05). Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 ± 275 and 381 ± 222 ng · hour/mL, 53.3 ± 26.8 and 43.6 ± 21.7 ng/mL, 1.9 ± 1.4 and 2± 1.4 hours, and 5.21 ± 1.78 and 6.19 ± 1.99 hours, respectively. These values were not significantly different (P > .05). In summary, this study showed that cisplatin and 5‐FU did not significantly alter the pharmacokinetics of oral ondansetron in cancer patients during the 5 days of chemotherapy. Oral bioavailability of ondansetron appeared to be greater in cancer patients than in healthy subjects. 1994 American College of Clinical Pharmacology

AB - The effect of a typical 5‐day chemotherapy treatment with cisplatin (20–40 mg/m 2 per day) and 5‐fluorouracil (5‐FU, 1 gm/m 2 per day) on the pharmacokinetics of ondansetron was investigated. Twenty cancer patients received 8 mg of ondansetron in three periods, including an oral tablet on day 1, an intravenous infusion on day 4, and an oral tablet on day 5. Absolute bioavailability after the oral dosing on day 1 was 87.5 ± 31.3%, and on day 5 was 85.2 ± 22.1% (P > .05). Mean values of AUC, Cmax, Tmax, and half life on days 1 and 5 were 399 ± 275 and 381 ± 222 ng · hour/mL, 53.3 ± 26.8 and 43.6 ± 21.7 ng/mL, 1.9 ± 1.4 and 2± 1.4 hours, and 5.21 ± 1.78 and 6.19 ± 1.99 hours, respectively. These values were not significantly different (P > .05). In summary, this study showed that cisplatin and 5‐FU did not significantly alter the pharmacokinetics of oral ondansetron in cancer patients during the 5 days of chemotherapy. Oral bioavailability of ondansetron appeared to be greater in cancer patients than in healthy subjects. 1994 American College of Clinical Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=0028247173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028247173&partnerID=8YFLogxK

U2 - 10.1002/j.1552-4604.1994.tb02038.x

DO - 10.1002/j.1552-4604.1994.tb02038.x

M3 - Article

VL - 34

SP - 767

EP - 773

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 7

ER -